Medical Economics March 25, 2025
Todd Shryock

Key Takeaways

  • Dawes-Redman CTG Analysis, now FDA-approved, enhances fetal monitoring by improving trace interpretation and reducing adverse outcomes for newborns.
  • The system evaluates basal heart rate, sinusoidal rhythms, and short-term variation, providing an objective assessment to standardize maternity care.
  • Supported by over 125 peer-reviewed studies, the technology analyzes healthy traces in ten minutes, improving efficiency.
  • Available in Huntleigh’s Sonicaid TEAM3 and OBIX BeCA monitors, it is expected to significantly improve U.S. maternity care.

FDA approves Dawes-Redman CTG analysis for U.S. use, enhancing fetal monitoring

Huntleigh Healthcare announced that its Dawes-Redman CTG Analysis has received approval from the U.S. Food and Drug Administration, boosting fetal monitoring technology. This milestone is expected to aid clinicians in improving trace interpretation and...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies, Medical Devices, Patient / Consumer, Provider
Related Articles:
Check Out the Future of Medtech: A Preview of Device and Diagnostics INVEST Pitch Perfect Finalists
Philips innovations for sustainability and a better environment
The Best Non-Prescription Migraine Treatment: 5 Tech Devices for Pain Relief
DME Providers Lead to Better CGM Adherence and Lower Healthcare Costs Compared to Pharmacies
For patients with diabetes, use of glucose monitors depends on how they get them

Share This Article